TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CSL ( (AU:CSL) ) has issued an announcement.
CSL Limited has announced an update regarding its ongoing on-market buy-back program, with a recent purchase of 42,359 ordinary fully paid securities. This buy-back initiative, which began on August 20, 2025, is part of CSL’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting the company’s commitment to maintaining a balanced approach to capital management.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$283.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company that operates in the healthcare industry, focusing on the development and delivery of innovative medicines and vaccines. The company is known for its work in plasma-derived therapies, vaccines, and recombinant proteins, serving a diverse range of markets worldwide.
Average Trading Volume: 1,187,657
Technical Sentiment Signal: Sell
Current Market Cap: A$89B
Learn more about CSL stock on TipRanks’ Stock Analysis page.